NCT05674656 - Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

May 3, 2028

Conditions

HIV Infections

Interventions

DRUG

Dolutegravir/Rilpivirine FDC

Dolutegravir/Rilpivirine will be administered.

Trial Locations (8)

RECRUITING

GSK Investigational Site, Washington D.C.

RECRUITING

GSK Investigational Site, Atlanta

RECRUITING

GSK Investigational Site, Miami

COMPLETED

GSK Investigational Site, Fort Lauderdale

RECRUITING

GSK Investigational Site, Tampa

RECRUITING

GSK Investigational Site, Houston

RECRUITING

GSK Investigational Site, Houston

RECRUITING

GSK Investigational Site, Long Beach